rood blauwe elepsis logo Belegger.nl

Bericht van CEO Avantium

7 Posts
| Omlaag ↓
  1. Guan1969! 3 september 2024 20:35
    Tom van Aken



    Chief Executive Officer at Avantium

    September 3, 2024

    As the CEO of Avantium NV, a listed company, I oversee how the company reports on financial results and progress. Since our H1 2024 results were published on August 22, we have seen the investor community responding to the results and the increase in the capex estimate of our FDCA Flagship Plant in Delfzijl. Many investors only focused on the capex increase, overlooking the unchanged timelines of this project and that we are finalizing construction. Please keep in mind that setbacks, like this capex increase, are typical for an innovative company like Avantium.

    ?? Innovation is a journey filled with both highs and challenging setbacks. It’s a dynamic process where breakthroughs and obstacles go hand in hand. For a company like Avantium, transitioning from an R&D company to a commercial organization, these experiences are part of the growth process. Managing a complex project like this, constructing a pioneering chemical manufacturing plant, a first of a kind in the world, is a huge task that comes with its own set of challenges. It’s the first time in its history that Avantium is undertaking a capital investment project of this scale and complexity, and while capex increases are common in such endeavors, they are obviously more noticeable for a newer company that is listed on the stock exchange. Petrochemical giants generally don’t report about them because these capex increases are not material to them, or they have more fat in their balance sheet to compensate for them.

    No such thing for Avantium, and therefore we report these developments in a transparent manner. Ultimately, the journey of innovation is about navigating through these challenges with resilience and determination. I believe that our team has shown over and over again that we are capable to overcome such setbacks, and remain focused on reaching the end goal. Challenges aside, we need to recognize that such setbacks do not diminish the overall business case, especially with a technology licensing business model in place – as was eloquently explained by Willem Frens on LinkedIn.

    ? Fast-forward to Friday, August 30. An analyst from ABN AMRO released a research note on Avantium, leading to a 15% drop in our share price that same day. The share price development was frustrating for the Avantium team, as we had limited control over the situation. For those unfamiliar with the structure of financial institutions, research teams operate independently from their other departments like corporate finance and debt finance. They provide analysis for institutional/ professional investors such as pension and investment funds. In this instance, the research report contained several factual errors and misrepresentations of what management had indicated during the analyst call of August 21. Unfortunately, the report had not been shared with us for fact-checking prior to its release. After release of the report, Avantium took immediate action, providing feedback to the analyst. The report was corrected and redistributed at the end of the market day. The damage was already done for Avantium and its shareholders.

    ? Despite the drop of our share price, our commitment to our long-term vision remains unwavering. We continue to focus on our mission and the broader impact we aim to achieve. Our ambition is to fundamentally change the way we produce, use and discard plastics. We aim to lead the transition from today’s fossil-based plastic materials to renewable and circular alternatives. Today’s plastics contribute significantly to carbon emissions and environmental harm as plastic waste. Addressing this issue is one of the major challenges of our generation. This transformation is difficult: it requires time, capital and courage. Don’t get me wrong: we don’t see this as an idealistic endeavour but we view this as the biggest business opportunity to create value for our shareholders. We have always emphasized that this is a long-term effort. While short-term setbacks can be distracting, they do not shake my confidence that we are on the right track.

    ?? We will continue to focus on completing the construction of our FDCA Flagship Plant and successfully starting it up. It will be an incredible moment to open the plant in October 2024 and even more to see PEF products in our supermarkets, refrigerators and wardrobes. Once the plant is operational, we can move ahead with technology licensing to ensure that FDCA and PEF are produced around the globe to realize its full potential.

    A major thank you to all investors, partners and colleagues who are supporting us on this amazing journey! We are on our way to successfully complete it.
  2. forum rang 4 putdeksel 3 september 2024 20:40
    Sorry, maar wat een jankstuk van deze CEO.

    - Bagatelliseert een tekortschietende raming, als of het normaal is dat je je aandeelhouders een te rooskleurig plaatje voorschotelt.
    - Geeft de analist de schuld van slechte uitleg van eigen verhaal. Had je maar duidelijker moeten zijn, pik!
  3. forum rang 5 silverbullet 5 september 2024 07:29
    quote:

    gaytrader schreef op 5 september 2024 00:29:

    En zo is het, Putdekselat Avantium legt het juist goed uit!!!
    Putdeksel legt het heel goed uit.

    CEO is er voor de aandeelhouder.

    Overigens is wel een hele mond vol..
    Tom van Aken Chief Executive Officer
    .
  4. forum rang 6 Tordan 5 september 2024 09:04
    Als je als CEO vindt dat je moet reageren wees dan ook een kerel en zeg hoeveel je tekort komt, wanneer en wie dat gaan betalen.
    Wat evt de verwatering gaat worden en wat dat betekent voor de aandeelhouders.
    Dit is eerder zielig dan knap.
  5. forum rang 5 silverbullet 5 september 2024 09:13
    quote:

    Tordan schreef op 5 september 2024 09:04:

    Als je als CEO vindt dat je moet reageren wees dan ook een kerel en zeg hoeveel je tekort komt, wanneer en wie dat gaan betalen.
    Wat evt de verwatering gaat worden en wat dat betekent voor de aandeelhouders.
    Dit is eerder zielig dan knap.
    Precies, een heldere uitleg

    Je bent in dienst voor je aandeelhouders en deze te informeren ipv druk te zijn met een "praatjes vullen geen gaatjes" publicatie en je verschuilen achter anderen
7 Posts
|Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.098
AB InBev 2 5.525
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.871
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.773
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.766
Aedifica 3 924
Aegon 3.258 322.967
AFC Ajax 538 7.088
Affimed NV 2 6.297
ageas 5.844 109.896
Agfa-Gevaert 14 2.052
Ahold 3.538 74.343
Air France - KLM 1.025 35.224
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.046
Alfen 16 25.027
Allfunds Group 4 1.511
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.510
AMG 971 134.022
AMS 3 73
Amsterdam Commodities 305 6.738
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.027
Apollo Alternative Assets 1 17
Apple 5 384
Arcadis 252 8.787
Arcelor Mittal 2.034 320.852
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.335
Aroundtown SA 1 220
Arrowhead Research 5 9.748
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.479
ASML 1.766 108.891
ASR Nederland 21 4.502
ATAI Life Sciences 1 7
Atenor Group 1 521
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.691
Axsome Therapeutics 1 177
Azelis Group 1 66
Azerion 7 3.412